BackTable Vascular & Interventional Ep. 547 Intratumoral Oncolytic Treatments for Metastatic Melanoma: A Multidisciplinary Approach with Dr. Riad Salem and Dr. Sunandana Chandra
May 27, 2025
Dr. Sunandana Chandra, a medical oncologist and director of melanoma care at Northwestern, joins Dr. Riad Salem, an interventional oncologist specializing in metastatic melanoma treatments. They discuss the evolution of melanoma management, highlighting innovative approaches like immunotherapy and intratumoral oncolytic viruses. The conversation dives into key clinical trials, including IGNYTE-3, and best practices for administering therapies. Their collaborative approach showcases the importance of multidisciplinary teams in enhancing patient-centered care and improving outcomes in advanced melanoma.
AI Snips
Chapters
Transcript
Episode notes
Half of Patients Resist Immunotherapy
- About 50% of advanced melanoma patients have resistance to immunotherapy, needing alternative treatments.
- Novel therapies like targeted drugs and intratumoral oncolytics become crucial for these refractory cases.
RP1 Oncolytic Virus Shows Promise
- Intratumoral oncolytic virus RP1 plus nivolumab shows a 33% response rate in advanced PD-1 refractory melanoma.
- This response is remarkable because these patients previously failed standard immunotherapies.
RP1 Induces Systemic Abscopal Effect
- RP1 triggers local tumor death and systemic immune activation causing shrinkage of even uninjected tumors.
- This abscopal effect evidences a true systemic anti-tumor benefit from intratumoral therapy.